Lyka Labs

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE933A01014
  • NSEID: LYKALABS
  • BSEID: 500259
INR
68.96
-3.49 (-4.82%)
BSENSE

Jun 11, 03:30 PM

BSE+NSE Vol: 1.17 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Ambalal Sarabhai
BDH Industries
Trident Lifeline
Gennex Lab.
Medicamen Biotec
Zenotech Lab.
Everest Organics
Lyka Labs
Astonea Labs
Sat Kartar Life
Infinium Pharma

Why is Lyka Labs Ltd ?

1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Operating profit has grown by an annual rate -201.29% of over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) of 2.30 times
2
The company has declared Negative results for the last 3 consecutive quarters
  • PBT LESS OI(Q) At Rs -9.20 cr has Fallen at -518.18%
  • ROCE(HY) Lowest at -6.10%
  • NET SALES(Q) Lowest at Rs 28.03 cr
3
Risky - Negative EBITDA
  • The company has recorded a negative EBITDA of Rs. -3.66 cr
  • Over the past year, while the stock has generated a return of -41.76%, its profits have fallen by -225.3%
  • The stock is trading risky as compared to its average historical valuations
4
Underperformed the market in the last 1 year
  • Even though the market (BSE500) generated negative returns of -5.53% in the last 1 year, its fall in the stock was much higher with a return of -41.76%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Lyka Labs for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Lyka Labs
-41.76%
-0.91
46.09%
Sensex
-10.52%
-0.81
13.06%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
8.29%
EBIT Growth (5y)
-201.29%
EBIT to Interest (avg)
1.22
Debt to EBITDA (avg)
1.26
Net Debt to Equity (avg)
0.51
Sales to Capital Employed (avg)
0.97
Tax Ratio
11.38%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.95%
ROCE (avg)
14.94%
ROE (avg)
69.08%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
33
Price to Book Value
2.65
EV to EBIT
-24.17
EV to EBITDA
-79.96
EV to Capital Employed
2.09
EV to Sales
2.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.66%
ROE (Latest)
-10.87%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company
Icon
NO KEY POSITIVE TRIGGERS
-13What is not working for the Company
PBT LESS OI(Q)

At Rs -9.20 cr has Fallen at -518.18%

ROCE(HY)

Lowest at -6.10%

NET SALES(Q)

Lowest at Rs 28.03 cr

PBDIT(Q)

Lowest at Rs -6.46 cr.

OPERATING PROFIT TO NET SALES (Q)

Lowest at -23.05%

EPS(Q)

Lowest at Rs -2.13

Loading Valuation Snapshot...

Here's what is not working for Lyka Labs

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs -9.20 cr has Fallen at -518.18%
Year on Year (YoY)
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Net Sales - Quarterly
At Rs 28.03 cr has Fallen at -16.15%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very negative

Net Sales (Rs Cr)

Net Sales - Quarterly
Lowest at Rs 28.03 cr
in the last five quarters
MOJO Watch
Near term sales trend is negative

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Lowest at Rs -6.46 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is negative

Operating Profit (Rs Cr)

Operating Profit Margin - Quarterly
Lowest at -23.05%
in the last five quarters
MOJO Watch
Company's efficiency has deteriorated

Operating Profit to Sales

Profit Before Tax less Other Income (PBT) - Quarterly
Lowest at Rs -9.20 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is negative

PBT less Other Income (Rs Cr)

Earnings per Share (EPS) - Quarterly
Lowest at Rs -2.13
in the last five quarters
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (Rs)